NovaBay Pharmaceuticals Reports 2022 Fourth Quarter and Full Year Financial Results
NovaBay Pharmaceuticals reported a strong financial performance for the fourth quarter and full year 2022, with net product revenue increasing by 15% in Q4 to $3.6 million, and by 41% year-over-year to $14.4 million. The significant growth was fueled by a 143% surge in wound care revenue and successful digital marketing optimization, leading to lower marketing expenses. However, gross margin for Q4 declined to 48% from 53% due to higher sales of lower margin products, and the company recorded a net loss of $8.2 million in Q4, driven primarily by a $6.7 million non-cash impairment charge related to DERMAdoctor assets.
- Product sales increased by 15% for Q4 and 41% for the year.
- Wound care revenue surged by 143% year-over-year.
- Digital marketing optimization reduced expenses by 4% while increasing revenue.
- Net loss attributable to common stockholders was $8.2 million in Q4.
- Gross margin declined to 48% in Q4 from 53% in the prior year.
- Non-cash impairment charges of $6.7 million impacted financial results.
-
Product sales increased
15% for the quarter and41% for the year, driven by increasingly diversified revenue streams -
Wound care revenue increased
143% year over year - Digital marketing program optimization continued to drive higher product sales on lower marketing spend
- Eyecare portfolio recently expanded with the introduction of the Avenova® oral supplement and Eyeganics Organic Tears
Conference call begins at
“Product sales for the fourth quarter increased
“We recently added a differentiated, high-quality OTC product to our eyecare portfolio, further reinforcing NovaBay as a one-stop destination for customers seeking relief from the symptoms of dry eye and other common eye frustrations,” he added. “Our new oral supplements are formulated with the rare maqui berry, which is shown to be highly effective for relief of dry eye symptoms. We also began co-promoting Eyeganics Organic Tears, the only
Fourth Quarter Financial Results
Net product revenue for the fourth quarter of 2022 was
Gross margin on net product revenue for the fourth quarter of 2022 was
Sales and marketing expenses were
NovaBay recorded non-cash impairment charges of
Non-cash gain on changes in fair value of warrant liability for the fourth quarter of 2022 was
Other expense, net for the fourth quarter of 2022 was
Net loss attributable to common stockholders for the fourth quarter of 2022 was
Full Year Financial Results
Net product revenue for 2022 was
Gross margin on net product revenue for 2022 was
For 2022, sales and marketing expenses decreased by
Non-cash loss on the modification of common stock warrants for 2022 was
The net loss attributable to common stockholders for 2022 was
NovaBay had cash and cash equivalents of
Conference Call
NovaBay management will host an investment community conference call today beginning at
Stockholders and other interested parties may also participate in the conference call by dialing 866-777-2509 from within the
A live webcast of the call will be available here and will be archived for 90 days. A replay of the call will be available beginning two hours after the call ends through
About
Forward-Looking Statements
This release contains information about management's view of the Company's future expectations, plans and prospects that constitute forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the fact that they do not relate strictly to historic or current facts. Such forward-looking statements are based upon management’s current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding our business strategies, commercial progress, current and potential future product offerings, the continuing integration of DERMAdoctor, expanded access to our products, and any future revenue, and the timing of such revenue, that may result from selling these products, as well as generally the Company’s expected future financial results. These statements involve risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by these forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to the integration of DERMAdoctor’s business with the Company’s business (and further related impairments to goodwill), the size of the potential market for our products, the Company’s products not being able to penetrate one or more targeted markets and the Company’s ability to continue as a going concern and revenues (or the execution on capital raise opportunities) not being sufficient to meet the Company’s cash needs. Other risks relating to NovaBay’s business, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay’s latest Form 10-K/Q filings with the
Socialize and Stay Informed on NovaBay’s Progress
Like us on Facebook
Follow us on Twitter
Connect with NovaBay on LinkedIn
Visit NovaBay’s Website
Avenova Purchasing Information
For NovaBay Avenova purchasing information:
Please call 800-890-0329 or email sales@avenova.com
Avenova.com
DERMAdoctor Purchasing Information
For DERMAdoctor purchasing information:
Please call 877-337-6237 or email service@dermadoctor.com
DERMAdoctor.com
|
||||||||
CONSOLIDATED BALANCE SHEETS |
||||||||
(in thousands, except par value amounts) |
||||||||
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
||
|
|
2022 |
|
|
2021 |
|
||
|
|
|
|
|
|
|
|
|
ASSETS |
|
|
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
5,362 |
|
|
$ |
7,504 |
|
Accounts receivable, net of allowance for doubtful accounts ( |
|
|
1,973 |
|
|
|
1,668 |
|
Inventory, net of allowance for excess and obsolete inventory and lower of cost or estimated net realizable value adjustments ( |
|
|
3,437 |
|
|
|
3,220 |
|
Prepaid expenses and other current assets |
|
|
560 |
|
|
|
778 |
|
Total current assets |
|
|
11,332 |
|
|
|
13,170 |
|
Operating lease right-of-use assets |
|
|
1,831 |
|
|
|
411 |
|
Property and equipment, net |
|
|
119 |
|
|
|
193 |
|
|
|
|
348 |
|
|
|
4,528 |
|
Other intangible assets, net |
|
|
2,280 |
|
|
|
5,200 |
|
Other assets |
|
|
489 |
|
|
|
476 |
|
TOTAL ASSETS |
|
$ |
16,399 |
|
|
$ |
23,978 |
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS' EQUITY |
|
|
|
|
|
|
|
|
Liabilities: |
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
1,080 |
|
|
$ |
1,045 |
|
Accrued liabilities |
|
|
2,724 |
|
|
|
2,092 |
|
Line of credit |
|
|
— |
|
|
|
105 |
|
Operating lease liabilities |
|
|
453 |
|
|
|
200 |
|
Total current liabilities |
|
|
4,257 |
|
|
|
3,442 |
|
Operating lease liabilities-non-current |
|
|
1,588 |
|
|
|
246 |
|
Warrant liability |
|
|
— |
|
|
|
9,558 |
|
Contingent earnout liability |
|
|
— |
|
|
|
561 |
|
Total liabilities |
|
|
5,845 |
|
|
|
13,807 |
|
Commitments & contingencies |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders' equity: |
|
|
|
|
|
|
|
|
Preferred stock, |
|
|
|
|
|
|
||
Series B preferred stock; 12 and 14 shares issued and outstanding at |
|
|
570 |
|
|
|
680 |
|
Series C preferred stock; 2 and no shares issued and outstanding at |
|
|
2,403 |
|
|
|
— |
|
Common stock, |
|
|
652 |
|
|
|
478 |
|
Additional paid-in capital |
|
|
165,081 |
|
|
|
150,900 |
|
Accumulated deficit |
|
|
(158,152 |
) |
|
|
(141,887 |
) |
Total stockholders' equity |
|
|
10,554 |
|
|
|
10,171 |
|
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY |
|
$ |
16,399 |
|
|
$ |
23,978 |
|
|
||||||||||||||||||||||
CONSOLIDATED STATEMENTS OF OPERATIONS |
||||||||||||||||||||||
(in thousands, except per share data) |
||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
|
|
|
|
Three Months Ended |
|
Year Ended |
||||||||||||||
|
|
|
|
|
|
|
2022 |
|
|
|
|
2021 |
|
|
|
2022 |
|
|
|
|
2021 |
|
Sales: | ||||||||||||||||||||||
Product revenue, net | $ | 3,631 |
|
$ | 3,167 |
|
$ | 14,374 |
|
$ | 10,180 |
|
||||||||||
Other revenue, net | 12 |
|
5 |
|
30 |
|
24 |
|
||||||||||||||
Total sales, net | 3,643 |
|
3,172 |
|
14,404 |
|
10,204 |
|
||||||||||||||
Cost of goods sold | 1,888 |
|
1,495 |
|
6,623 |
|
3,689 |
|
||||||||||||||
Gross profit | 1,755 |
|
1,677 |
|
7,781 |
|
6,515 |
|
||||||||||||||
Operating expenses: | ||||||||||||||||||||||
Research and development | 66 |
|
9 |
|
174 |
|
44 |
|
||||||||||||||
Sales and marketing | 1,938 |
|
2,150 |
|
7,798 |
|
8,093 |
|
||||||||||||||
General and administrative | 2,440 |
|
2,713 |
|
7,489 |
|
7,240 |
|
||||||||||||||
6,737 |
|
- |
|
6,737 |
|
- |
|
|||||||||||||||
Total operating expenses | 11,181 |
|
4,872 |
|
22,198 |
|
15,377 |
|
||||||||||||||
Operating loss | (9,426 |
) |
(3,195 |
) |
(14,417 |
) |
(8,862 |
) |
||||||||||||||
Non-cash loss on modification of common stock warrants | - |
|
- |
|
(1,922 |
) |
- |
|
||||||||||||||
Non-cash gain on changes in fair value of warrant liability | 976 |
|
4,615 |
|
5,446 |
|
4,615 |
|
||||||||||||||
Non-cash gain on changes in fair value of contingent liability | 342 |
|
- |
|
561 |
|
- |
|
||||||||||||||
Other expense, net | (98 |
) |
(1,579 |
) |
(276 |
) |
(1,577 |
) |
||||||||||||||
Loss before provision for income taxes | (8,206 |
) |
(159 |
) |
(10,608 |
) |
(5,824 |
) |
||||||||||||||
Provision for income taxes | — |
|
- |
|
— |
|
- |
|
||||||||||||||
Net loss | $ | (8,206 |
) |
$ | (159 |
) |
$ | (10,608 |
) |
$ | (5,824 |
) |
||||||||||
Less: Preferred deemed dividend | - |
|
735 |
|
- |
|
735 |
|
||||||||||||||
Less: Retained earnings reduction related to preferred stock down round feature triggered | - |
|
- |
|
5,657 |
|
- |
|
||||||||||||||
Net loss attributable to common stockholders | $ | (8,206 |
) |
$ | (894 |
) |
$ | (16,265 |
) |
$ | (6,559 |
) |
||||||||||
Net loss per share attributable to common stockholders (basic and diluted) | $ | (4.33 |
) |
$ | (0.69 |
) |
$ | (10.10 |
) |
$ | (4.81 |
) |
||||||||||
Weighted-average shares of common stock used in computing net loss per share attributable to common stockholders (basic and diluted) |
1,893 |
|
1,295 |
|
1,610 |
|
1,365 |
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20230330005709/en/
NovaBay Contact
Chief Executive Officer and General Counsel
510-899-8800
jhall@novabay.com
Investor Contact
LHA Investor Relations
310-691-7100
jcain@lhai.com
Source:
FAQ
What were NovaBay Pharmaceuticals' Q4 2022 product sales results?
How did NovaBay perform in 2022 compared to 2021?
What was the net loss reported by NovaBay in Q4 2022?
How did marketing expenses impact NovaBay's financial results?